Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV6 | Q9H1D0 | 6/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | CCR3 | P51677 | 1/20 | 0.50 |
| ▸ | MC4R | P32245 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1204182 | 0.94 | TRPV6 (0.53) | TRPV6SIGMAR1RECQLSMN1; SMN2TSHR | |
| SCHEMBL4797625 | 0.92 | SIGMAR1 (0.69) | TRPV6SIGMAR1RECQLSMN1; SMN2TSHR | |
| SCHEMBL1206045 | 0.87 | DRD2 (0.59) | SIGMAR1RECQLSMN1; SMN2TSHRACHE | |
| SCHEMBL3709310 | 0.86 | RECQL (0.70) | TRPV6SIGMAR1RECQLSMN1; SMN2TSHR | |
| Hydrochloric Acid SCHEMBL3706762 | 0.85 | RECQL (0.68) | TRPV6SIGMAR1RECQLSMN1; SMN2TSHR | |
| SCHEMBL13943667 | 0.85 | SIGMAR1 (0.64) | TRPV6SIGMAR1RECQLSMN1; SMN2TSHR | |
| SCHEMBL18177889 | 0.84 | ACHE (0.70) | TRPV6SIGMAR1RECQLSMN1; SMN2TSHR | |
| SCHEMBL22834418 | 0.84 | TRPV6 (0.58) | TRPV6SIGMAR1RECQLSMN1; SMN2TSHR | |
| SCHEMBL7474570 | 0.84 | TRPV6 (0.58) | TRPV6SIGMAR1RECQLSMN1; SMN2TSHR | |
| SCHEMBL7899060 | 0.84 | TRPV6 (0.58) | TRPV6SIGMAR1RECQLSMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205603-B1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LTD (GB) | 2014-01-15 | — | — | EP | claimed |
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| EP-2610256-B1 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LTD (GB) | 2016-04-27 | — | — | EP | disclosed |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-9133199-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-9133199-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-8563542-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2013-10-22 | — | — | US | disclosed |
| EP-2610256-A1 | Pyrimidine derivatives as protein kinase inhibitors | Cyclacel Limited (GB) | 2013-07-03 | — | — | EP | disclosed |
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| EP-2205603-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Cyclacel Limited (GB) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009040556-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2009-04-02 | — | — | WO | disclosed |
| US-6444677-B2 | TREATMENT OF INFLAMMATION, CARDIOVASCULAR DISEASE, PAIN, ETC. | PFIZER INC. | 2002-09-03 | — | — | US | disclosed |
| US-20010046993-A1 | 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | IKEDA TAKAFUMI (JP) | 2001-11-29 | — | — | US | disclosed |
| EP-1106614-A1 | 5-Membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. (US) | 2001-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CDK7, CDK9, CDK8 | TRPV6 3484/4885SIGMAR1 1497/4885RECQL 1373/4885 |
| US-20010046993-A1 | 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, CNR2 | TRPV6 53/4885SIGMAR1 127/4885RECQL 2401/4885 |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | DCK, DTYMK, TK1 | TRPV6 4286/4885SIGMAR1 4621/4885RECQL 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.